S. 2476 · 115th Congress
Expanding Access to Low Cost Generic Drugs Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
SmithSponsorNo cosponsors.
This bill amends the Federal Food, Drug, and Cosmetic Act to disqualify from receiving market exclusivity a generic drug manufacturer who enters into an agreement with the patent holder for a brand name drug to delay getting the generic drug approved or to delay marketing it.
What it does: CRS summary · Introduced in Senate · Feb 28, 2018
Expanding Access to Low Cost Generic Drugs Act
This bill amends the Federal Food, Drug, and Cosmetic Act to disqualify from receiving market exclusivity a generic drug manufacturer who enters into an agreement with the patent holder for a brand name drug to delay getting the generic drug approved or to delay marketing it.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Expanding Access to Low Cost Generic Drugs Act
Latest action (Feb 28, 2018): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Feb 28, 2018
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.